Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.36 -0.35 (-0.60%)
Streaming Delayed Price Updated: 12:40 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,359,505
Open 58.21
Bid (Size) 58.36 (800)
Ask (Size) 58.37 (600)
Prev. Close 58.71
Today's Range 58.10 - 59.12
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+9.2%
+9.2%
1 Month
-0.3%
-0.3%
3 Month
+6.9%
+6.9%
6 Month
+34.5%
+34.5%
1 Year
+20.4%
+20.4%

More News

Read More
News headline image
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Question
Via StockStory
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Via The Motley Fool
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
Via MarketMinute
Topics Artificial Intelligence
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Via MarketMinute
News headline image
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Value Stocks Walking a Fine Line
Via StockStory
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
News headline image
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Via StockStory
News headline image
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
From Bristol Myers Squibb
Via Business Wire
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
Via MarketMinute
Topics Intellectual Property
News headline image
Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb
Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 58.36
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 04/27/26 12:40 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 129.68B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 130B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>